JP2018532813A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018532813A5 JP2018532813A5 JP2018543291A JP2018543291A JP2018532813A5 JP 2018532813 A5 JP2018532813 A5 JP 2018532813A5 JP 2018543291 A JP2018543291 A JP 2018543291A JP 2018543291 A JP2018543291 A JP 2018543291A JP 2018532813 A5 JP2018532813 A5 JP 2018532813A5
- Authority
- JP
- Japan
- Prior art keywords
- vaccine according
- antigen
- vaccine
- protein
- chlamydia species
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960005486 vaccines Drugs 0.000 claims 24
- 239000000427 antigen Substances 0.000 claims 17
- 102000038129 antigens Human genes 0.000 claims 17
- 108091007172 antigens Proteins 0.000 claims 17
- 241000606161 Chlamydia Species 0.000 claims 10
- 102000004169 proteins and genes Human genes 0.000 claims 7
- 108090000623 proteins and genes Proteins 0.000 claims 7
- 150000001720 carbohydrates Chemical class 0.000 claims 6
- 235000014633 carbohydrates Nutrition 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 230000002458 infectious Effects 0.000 claims 3
- 230000003612 virological Effects 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 claims 2
- 241001495184 Chlamydia sp. Species 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 201000009910 diseases by infectious agent Diseases 0.000 claims 1
- 230000002708 enhancing Effects 0.000 claims 1
- 102000014611 env Gene Products Human genes 0.000 claims 1
- 108010078428 env Gene Products Proteins 0.000 claims 1
- 230000004727 humoral immunity Effects 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 108060005683 ompA Proteins 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
Claims (22)
- 抗原と、クラミジア種のタンパク質、ペプチド、若しくは炭水化物、又はそれらの断片と、を含むワクチンであって、前記抗原がクラミジア種に由来しない、ワクチン。
- 前記クラミジア種が、C.トラコマチス、C.シッタシ、C.ムリダルム、又はC.ニューモニエを含む、請求項1に記載のワクチン。
- 前記クラミジア種が、不活性化される、請求項1又は2に記載のワクチン。
- 前記クラミジア種のタンパク質、ペプチド、若しくは炭水化物、又はそれらの断片が、クラミジアの主要外膜(MOMP)タンパク質を含む、請求項1〜3のいずれか一項に記載のワクチン。
- 前記ワクチンが、2つ以上の抗原を含む、請求項1〜4のいずれか一項に記載のワクチン。
- 前記ワクチンが、3つ以上の抗原を含む、請求項5に記載のワクチン。
- 前記抗原が、感染因子を含む、請求項1〜6のいずれか一項に記載のワクチン。
- 前記感染因子が、ウイルス性である、請求項7に記載のワクチン。
- 前記ウイルス性感染因子が、HIVである、請求項8に記載のワクチン。
- 前記抗原が、腫瘍関連抗原を含む、請求項1〜6のいずれか一項に記載のワクチン。
- 前記ワクチンが、前記抗原単独と比較して、特異的体液性免疫を高める、請求項1〜10のいずれか一項に記載のワクチン。
- 抗原と、クラミジア種のタンパク質、ペプチド、若しくは炭水化物、又はそれらの断片と、を含むキットであって、前記抗原がクラミジア種に由来しない、キット。
- 対象における疾患又は感染を予防又は治療するための、請求項1に記載のワクチン。
- 前記抗原が、ウイルス性である、請求項13に記載のワクチン。
- 前記抗原が、HIVに由来する、請求項14に記載のワクチン。
- 前記抗原が、envタンパク質、ペプチド、又はそれらの断片である、請求項15に記載のワクチン。
- 前記抗原が、腫瘍関連である、請求項13に記載のワクチン。
- 前記対象が、哺乳類である、請求項13〜17のいずれか一項に記載のワクチン。
- 前記哺乳類が、ヒトである、請求項18に記載のワクチン。
- 前記抗原と、前記クラミジア種のタンパク質、ペプチド、若しくは炭水化物、又はそれらの断片とが、同時に投与される、請求項13〜19のいずれか一項に記載のワクチン。
- 前記抗原が、前記クラミジア種のタンパク質、ペプチド、若しくは炭水化物、又はそれらの断片の前に投与される、請求項13〜19のいずれか一項に記載のワクチン。
- 前記抗原が、前記クラミジア種のタンパク質、ペプチド、若しくは炭水化物、又はそれらの断片の後に投与される、請求項13〜19のいずれか一項に記載のワクチン。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562253370P | 2015-11-10 | 2015-11-10 | |
US62/253,370 | 2015-11-10 | ||
PCT/US2016/061062 WO2017083337A1 (en) | 2015-11-10 | 2016-11-09 | Methods and compositions related to accelerated humoral affinity |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2018532813A JP2018532813A (ja) | 2018-11-08 |
JP2018532813A5 true JP2018532813A5 (ja) | 2019-12-19 |
JP7086000B2 JP7086000B2 (ja) | 2022-06-17 |
Family
ID=58695147
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018543291A Active JP7086000B2 (ja) | 2015-11-10 | 2016-11-09 | 体液性親和性の加速に関する方法及び組成物 |
Country Status (7)
Country | Link |
---|---|
US (2) | US10835601B2 (ja) |
EP (1) | EP3373961A4 (ja) |
JP (1) | JP7086000B2 (ja) |
CN (1) | CN108367058A (ja) |
AU (2) | AU2016354444B2 (ja) |
CA (1) | CA3004924A1 (ja) |
WO (1) | WO2017083337A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11850279B2 (en) * | 2016-07-13 | 2023-12-26 | Ohio State Innovation Foundation | Platforms and methods for optimizing host antigen presentation and host antitumor and antipathogen immunity |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5759551A (en) | 1993-04-27 | 1998-06-02 | United Biomedical, Inc. | Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines |
CA2175081A1 (en) * | 1993-11-03 | 1995-05-11 | James Evan Sandbulte | Vaccine and method for treatment of chlamydial infections |
GB9626864D0 (en) * | 1996-12-24 | 1997-02-12 | Smithkline Beecham Biolog | Vaccine |
US6001372A (en) | 1995-08-25 | 1999-12-14 | Wisconsin Alumni Research Foundation | Antigenic peptides of Chlamydia trachomatis |
WO1997026910A2 (de) | 1996-01-27 | 1997-07-31 | Max-Delbrück-Centrum für Molekulare Medizin | Tumorimpfstoff für die immuntherapie von malignen tumoren |
US6344202B1 (en) | 1996-07-12 | 2002-02-05 | University Of Manitoba | DNA immunization against chlaymdia infection |
US6465251B1 (en) | 1996-11-13 | 2002-10-15 | Dana-Farber Cancer Institute, Inc. | Method of promoting b-cell proliferation and activation with CD40 ligand and cyclosporin |
CA2216559A1 (en) | 1997-09-25 | 1999-03-25 | Michel Roberge | G2 checkpoint inhibitors and assay |
US7041490B1 (en) | 1997-11-28 | 2006-05-09 | Serono Genetics Institute, S.A. | Chlamydia trachomatis polynucleotides and vectors, recombinant host cells, DNA chips or kits containing the same |
MXPA01009256A (es) * | 1999-03-12 | 2003-07-14 | Aventis Pasteur | Antigenos de chlamydia y fragmentos de acido desoxirribonucleico correspondientes y usos de los mismos. |
US6225443B1 (en) | 1999-05-19 | 2001-05-01 | Wisconsin Alumni Research Foundation | Cytotoxic T lymphocyte epitopes of the major outer membrane protein of chlamydia trachomatis |
KR20020072277A (ko) | 1999-11-08 | 2002-09-14 | 아이덱 파마슈티칼즈 코포레이션 | 항-cd20 항체 및/또는 화학요법 및 방사선요법과결합하여 항-cd40l 항체를 이용한 b세포 악성종양의치료방법 |
DE19954514A1 (de) | 1999-11-12 | 2001-05-17 | Schoellhorn Volkmar | Verfahren zur Manipulation der Aktivität von Zellen |
MXPA02007473A (es) | 2000-02-01 | 2003-09-22 | Tanox Inc | Moleculas activadoras de celulas presentadoras de antigenos (apc) que se unen a cd40. |
WO2001094418A2 (en) | 2000-06-05 | 2001-12-13 | Corixa Corporation | Leader peptides for enhancing secretion of recombinant protein from a host cell |
EP1297005B1 (en) * | 2000-07-03 | 2009-08-26 | Novartis Vaccines and Diagnostics S.r.l. | Immunisation against chlamydia pneumoniae |
GB0103170D0 (en) | 2001-02-08 | 2001-03-28 | Smithkline Beecham Biolog | Vaccine composition |
US7537772B1 (en) | 2000-10-02 | 2009-05-26 | Emergent Product Development Gaithersburg Inc. | Chlamydia protein, gene sequence and the uses thereof |
US7731980B2 (en) | 2000-10-02 | 2010-06-08 | Emergent Product Development Gaithersburg Inc. | Chlamydia PMP proteins, gene sequences and uses thereof |
KR100982204B1 (ko) * | 2001-12-12 | 2010-09-14 | 노바티스 백신즈 앤드 다이아그노스틱스 에스.알.엘. | 클라미디아 트라코마티스에 대한 면역화 |
US20030118569A1 (en) | 2001-12-18 | 2003-06-26 | Bankert Richard B. | Method of enhancing immunogenicity by covalent linkage of antigens to proteins on the surface of dendritic cells |
ATE458496T1 (de) | 2002-01-14 | 2010-03-15 | Novartis Vaccines & Diagnostic | Hiv-vakzine und anwendungsverfahren |
GB0220194D0 (en) * | 2002-08-30 | 2002-10-09 | Chiron Spa | Improved vesicles |
DE10326187A1 (de) * | 2003-06-06 | 2005-01-05 | MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH | Zellen als Träger für Bakterien |
US7368537B2 (en) | 2003-07-15 | 2008-05-06 | Id Biomedical Corporation Of Quebec | Subunit vaccine against respiratory syncytial virus infection |
US20060121055A1 (en) * | 2004-12-06 | 2006-06-08 | Becton, Dickinson And Company, Inc. | Compositions with enhanced immunogenicity |
MX2007012108A (es) | 2005-03-31 | 2007-12-05 | Glaxosmithkline Biolog Sa | Vacunas contra infeccion por chlamydia. |
US8318906B2 (en) | 2005-04-15 | 2012-11-27 | The Regents Of The University Of California | EMP2 antibodies and their therapeutic uses |
CA2609038A1 (en) | 2005-05-18 | 2006-11-23 | Trinity Biosystems, Inc. | Methods and compositions for immunizing against chlamydia infection |
WO2006128296A1 (en) * | 2005-06-01 | 2006-12-07 | Sanofi Pasteur Limited | Pal-based chlamydia vaccine |
EP1912665B1 (en) | 2005-07-28 | 2011-01-26 | Pfizer Products Inc. | Vaccine against feline calicivirus (fcv) comprising a fcv capsid protein or an isolated fcv capsid protein comprising protein sequence seq id no: 13 or protein sequences having at least 95% identity thereto. |
WO2007110700A2 (en) * | 2005-12-22 | 2007-10-04 | Novartis Vaccines And Diagnostics, Srl. | Chlamydial antigens |
CN101426523B (zh) | 2006-04-27 | 2013-03-27 | 财团法人首尔大学校产学协力财团 | 基于负载了天然杀伤t细胞的配体、和抗原的b细胞的疫苗 |
US20140056967A1 (en) * | 2007-09-28 | 2014-02-27 | Glaxosmithkline Biologicals S.A. | Vaccines against chlamydial infection |
GB0911042D0 (en) | 2009-06-25 | 2009-08-12 | Istituto Superiore Di Sanito | Treatment of tumorigenic cells in solid tumours |
US9125899B1 (en) | 2010-06-17 | 2015-09-08 | Stc.Unm | Modulators of GTPases and their use |
JP5824870B2 (ja) | 2011-05-25 | 2015-12-02 | 株式会社リコー | 画像形成装置 |
BR112014007927B1 (pt) | 2011-10-06 | 2021-04-13 | Immunovaccine Technologies Inc | Composições de lipossoma compreendendo um adjuvante e usos das referidas composições e usos das referidas composições |
AU2014236340B2 (en) * | 2013-03-14 | 2019-01-17 | Massachusetts Institute Of Technology | Nanoparticle-based compositions |
PT2976355T (pt) | 2013-03-18 | 2020-04-02 | Statens Seruminstitut | Vacinas contra chlamydia sp |
AU2014296887A1 (en) | 2013-08-02 | 2016-01-28 | Aduro Biotech Holdings, Europe B.V. | Combining CD27 agonists and immune checkpoint inhibition for immune stimulation |
CN107206258A (zh) | 2015-02-10 | 2017-09-26 | 俄亥俄州创新基金会 | 衣原体激活的b细胞平台及其方法 |
-
2016
- 2016-11-09 CN CN201680072156.8A patent/CN108367058A/zh active Pending
- 2016-11-09 CA CA3004924A patent/CA3004924A1/en active Pending
- 2016-11-09 JP JP2018543291A patent/JP7086000B2/ja active Active
- 2016-11-09 AU AU2016354444A patent/AU2016354444B2/en active Active
- 2016-11-09 WO PCT/US2016/061062 patent/WO2017083337A1/en active Application Filing
- 2016-11-09 US US15/775,155 patent/US10835601B2/en active Active
- 2016-11-09 EP EP16864881.4A patent/EP3373961A4/en active Pending
-
2020
- 2020-09-30 US US17/038,423 patent/US20210015914A1/en not_active Abandoned
-
2021
- 2021-07-01 AU AU2021204628A patent/AU2021204628A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2016040284A5 (ja) | ||
EA200801798A1 (ru) | Виросомоподобные везикулы, содержащие антигены, производные от gp41 | |
WO2017123636A8 (en) | Dosage and administration of anti-c5 antibodies for treatment | |
AR082149A1 (es) | Anticuerpos contra el virus sincicial respiratorio (rsv) humano y metodos para su uso | |
JP2015524422A5 (ja) | ||
JP2014534202A5 (ja) | ||
WO2016100807A3 (en) | Human antibodies to influenza hemagglutinin | |
JP2016506416A5 (ja) | ||
WO2017079479A8 (en) | Neutralizing antibodies to hiv-1 gp41 and their use | |
AR068507A1 (es) | Construcciones vector fluorocarbonado-antigeno para el suministro de antigenos ifluenza | |
CY1118801T1 (el) | Πεπτιδια, προϊοντα συζευξης και μεθοδος για την αυξηση της ανοσογονικοτητας ενος εμβολιου | |
WO2016116905A9 (en) | Cmv antigens and uses thereof | |
JP2019504895A5 (ja) | ||
WO2016191641A3 (en) | Methods for enhancing antigen-specific immune responses using combination therapy comprising papillomavirus capsid antigens | |
JP2013523783A5 (ja) | ||
JP2016106117A5 (ja) | ||
JP2012519724A5 (ja) | ||
IN2012DN02692A (ja) | ||
ECSP024257A (es) | Proteinas antigenas del virus de la enfermedad de la mancha blanca en el camaron y usos de las mismas | |
HRP20171697T1 (hr) | Varijanta hiv gp-120 | |
WO2007005627A8 (en) | Tuberculosis antigen detection assays and vaccines | |
JP2015529677A5 (ja) | ||
JP2018532813A5 (ja) | ||
MX2018013685A (es) | Terapia de combinacion de cebadadura:refuerzo. | |
JP2006523185A5 (ja) |